• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . TLR5 versus TLR7/8 agonist-dependent modulation of the early gene expression response to inactivated influenza virus vaccine in newborn no

tetano

Editor, Senior Moderator
Vaccine


. 2026 Jan 12:74:128163.
doi: 10.1016/j.vaccine.2025.128163. Online ahead of print. TLR5 versus TLR7/8 agonist-dependent modulation of the early gene expression response to inactivated influenza virus vaccine in newborn nonhuman primates

Courtney L Page[SUP] 1 [/SUP], Beth C Holbrook[SUP] 1 [/SUP], Lance D Miller[SUP] 2 [/SUP], Jason M Grayson[SUP] 1 [/SUP], Martha A Alexander-Miller[SUP] 3 [/SUP]



Affiliations
Abstract

There is an urgent need for strategies that can improve vaccine immunogenicity, especially for vulnerable populations such as newborns and young infants. Growing evidence supports Toll-Like Receptor agonists (TLRa) as potent stimulatory molecules to increase vaccine efficacy. We have previously demonstrated that the inclusion of either flagellin (TLR5a) or R848 (TLR7/8a) in an inactivated influenza virus vaccine can improve responses in newborn NHP, with R848 being superior at providing protection upon challenge. This study aimed to identify early immune events triggered by either inactivated virus alone or in combination with R848 or flagellin using scRNA-seq analysis of draining lymph nodes (dLN) collected 24 h after vaccination. Our study reveals that globally, R848 enhanced gene expression associated with B cell activation, while flagellin was a stronger modulator of T cells. Analysis of distinct lymph node populations showed that surprisingly, while APCs had a potent transcriptional response to inactivated virus, we observed minimal additional changes in transcriptional activity with addition of a TLRa. In contrast, R848 had a potent effect on cellular translation, while flagellin resulted in increased expression of type I interferon genes in B cells. All vaccines resulted in a population of T cells bearing an interferon response signature that was further modified by TLRa inclusion. R848 uniquely increased the expression of genes involved with cellular migration and inflammation in this population, while flagellin increased genes involved in vesicular trafficking, cAMP responsiveness, and calcium signaling. Together, these results suggest R848 promotes newborn B cell activation and enhanced migration/retention in the dLN. In contrast, flagellin amplifies the type I interferon signature of B cells and had broad impacts on the responding T cell population. Our findings provide new insights into the modulation of early vaccine responses in newborns following administration of inactivated influenza virus, R848 and flagellin.

Keywords: Adjuvants; Draining lymph node; Flagellin; Inactivated influenza virus; Newborn; R848; Transcriptional profile; Vaccine.

 
Back
Top Bottom